Ardelyx Inc (ARDX)
Official siteHEALTHCARE • BIOTECHNOLOGY • NASDAQ
Market Cap: $776.74M
Last updated: Nov 17, 2026 at 11:05 AM ET
Ardelyx Inc (ARDX) Valuation Multiples
Ardelyx (ARDX) trades at 1.6x sales and 4.7x book value. Its P/S of 1.6x is below its 5-year median of 6.9x. Its forward P/E is 51.3x.
Current Multiples
| Multiple | Value |
|---|---|
| P/E (trailing) | N/A |
| Forward P/E | 51.3x |
| Price to sales | 1.6x |
| Price to book | 4.7x |
| PEG | N/A |
Historical Medians
Against its 10-year medians, its P/S is 84.3% below 10.2x and its P/B is 17.5% above 4.0x.
| Multiple | Current | 5-year median | 10-year median |
|---|---|---|---|
| P/S | 1.6x | 6.9x | 10.2x |
| P/B | 4.7x | 7.4x | 4.0x |
Valuation History
Over the 9 of the 10 year ends shown that have a P/S, its P/S ranged from 3.5x in 2025 to 93.2x in 2019. 2025 was the lowest of those years.
| Year end | Price | P/S | P/B |
|---|---|---|---|
| 2025 | $5.83 | 3.5x | 8.5x |
| 2024 | $5.07 | 3.6x | 7.1x |
| 2023 | $6.20 | 10.9x | 8.2x |
| 2022 | $2.85 | 10.2x | 5.6x |
| 2021 | $1.10 | 10.9x | 1.5x |
| 2020 | $6.47 | 76.6x | 4.7x |
| 2019 | $7.51 | 93.2x | 2.8x |
| 2018 | $1.79 | 33.4x | 1.0x |
| 2017 | $6.60 | 7.7x | 2.3x |
| 2016 | $14.20 | N/A | 3.5x |
GNG Valuation
| GNG view | Undervalued |
|---|
GNG fair value is part of GNG Pro. See plans
Frequently Asked Questions About ARDX
What is ARDX's forward P/E ratio?
Ardelyx has a forward P/E ratio of 51.3x.
Is ARDX stock overvalued?
GNG's valuation label for ARDX is Undervalued.
What is ARDX's price to sales ratio?
Ardelyx has a price to sales ratio of 1.6x.
ARDX pages: Overview, Earnings, Forecast, Financials, Valuation, Competitors, Government Contracts